According to Melbourne Litigation, the decision not protect this gene with a patent is bound to hurt Myriad’s Australian licensee, Genetic Technologies Ltd (ASX: GTG), which sells tests for it.
The HC held that while the invention claimed might be, in a formal sense, a product of human action, it was the existence of the information stored in the relevant sequences that was an essential element of the unpatentable invention as claimed.
Copy of the Decision Summary HERE.
We understand the commercial landscape and apply an approach that integrates our litigation expertise with practical, customised business solutions. Our long experience in business and law is applied to all cases and projects, whether for a complex corporate dispute or a straightforward contract breach, giving us an ability to anticipate likely outcomes and guide you through the options, as we have for many others, hundreds of times previously.
